Sbir topic 66 phase II: haptoglobin treatment to reduce complications of sickle cell disease
Ended Definitive Contract Awarded Last action
- Contract number
- HHSN268201400032C
- Awardee
-
Nanoshell Company, LLC UEI CR7UGP1QGP26
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $649,748
Award facts
- Opportunity
-
- PHS20121 Solicitation number
- A solicitation of the national institutes of health (NIH) and the centers for disease control and prevention (CDC) for small business innovation research (SBIR) contract proposals Award Notice · Posted Aug 5, 2011
- Contract value 50% obligated
-
- $649,748.00 Current, with exercised options
- $1,292,182.00 Potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 1 offer Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Layton, UT 84040, USA
- Research
- SBIR Program Phase II Action
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $649,748 |
About this award
This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the National Heart, Lung, and Blood Institute (NHLBI), a component of the U.S. Department of Health and Human Services (HHS), to Nanoshell Company, LLC, a woman-owned small business. The contract, valued at $1,292,182, is for the development of a haptoglobin treatment to reduce complications of sickle cell disease. The contract is a definitive, firm-fixed-price contract with a period of performance ending on June 30, 2016. As an SBIR Phase II contract, this award represents a follow-on to an earlier Phase I effort by the company.
Quick answers
Who was awarded contract HHSN268201400032C?
HHSN268201400032C was awarded to Nanoshell Company, LLC by National Heart Lung and Blood Institute (National Institutes of Health) on July 2, 2014.
How much is contract HHSN268201400032C worth?
The government has obligated $649,748 on HHSN268201400032C. Its potential value, with all options, is $1,292,182.
Was contract HHSN268201400032C competed?
The extent of competition for HHSN268201400032C was full and open competition after exclusion of sources. The government received 1 offer. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award